Who makes P-gp victim drug?

P-gp victim drug is developed by Kadmon, a Sanofi Company.

What development phase is P-gp victim drug in?

P-gp victim drug is in Phase 1.

Last reviewed 2026-04-19 · How we verify

P-gp victim drug

Kadmon, a Sanofi Company · Phase 1 active Small molecule

At a glance

Generic name	P-gp victim drug
Sponsor	Kadmon, a Sanofi Company
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects (PHASE1)
Clinical Trial to Assess Effect of Verapamil on Systemic Exposure of EP395 and Effect of EP395 on Systemic Exposure of Midazolam and Digoxin (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

P-gp victim drug CI brief — competitive landscape report
P-gp victim drug updates RSS · CI watch RSS
Kadmon, a Sanofi Company portfolio CI